Patents by Inventor Melissanne DE WISPELAERE

Melissanne DE WISPELAERE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lentiviral vector-based Japanese encephalitis immunogenic composition
    Patent number: 11779640
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: October 10, 2023
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
  • DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN
    Publication number: 20210338825
    Abstract: Disclosed are bifunctional compounds (degraders) that target hepatitis C virus (HCV) NS3/4A for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat HCV infection and HCV-associated diseases or disorders.
    Type: Application
    Filed: September 26, 2019
    Publication date: November 4, 2021
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Nathanael S. Gray, Tinghu Zhang, Priscilla Yang, Melissanne De Wispelaere, Guangyan Du
  • LENTIVIRAL VECTOR-BASED JAPANESE ENCEPHALITIS IMMUNOGENIC COMPOSITION
    Publication number: 20200230228
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Application
    Filed: February 19, 2020
    Publication date: July 23, 2020
    Inventors: Pierre CHARNEAU, Philippe DESPRES, Melissanne DE WISPELAERE, Philippe SOUQUE, Marie-Pascale FRENKIEL
  • Lentiviral vector-based Japanese encephalitis immunogenic composition
    Patent number: 10603374
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 31, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
  • HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES
    Publication number: 20190292178
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENV)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Application
    Filed: January 26, 2018
    Publication date: September 26, 2019
    Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Nathanael S. Gray, Priscilla L. Yang, Qingsong Liu, Mélissanne de Wispelaere
  • HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES
    Publication number: 20180265507
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENV)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Application
    Filed: January 26, 2018
    Publication date: September 20, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Nathanael S. Gray, Priscilla L. Yang, Qingsong Liu, Mélissanne de Wispelaere
  • Host targeted inhibitors of dengue virus and other viruses
    Patent number: 9879003
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 30, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Nathanael Gray, Priscilla Yang, Qingsong Liu, Mélissanne de Wispelaere
  • LENTIVIRAL VECTOR-BASED JAPANESE ENCEPHALITIS IMMUNOGENIC COMPOSITION
    Publication number: 20170319681
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Application
    Filed: December 7, 2015
    Publication date: November 9, 2017
    Inventors: Pierre CHARNEAU, Philippe DESPRES, Melissanne DE WISPELAERE, Philippe SOUQUE, Marie-Pascale FRENKIEL
  • HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES
    Publication number: 20150166532
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Application
    Filed: March 15, 2013
    Publication date: June 18, 2015
    Inventors: Nathanael Gray, Priscilla Yang, Qingsong Liu, Mélissanne de Wispelaere